Ariad submits ponatinib MAA

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) submitted an MAA to EMA for ponatinib to treat resistant or intolerant chronic myelogenous leukemia (CML) and Philadelphia-chromosome positive (Ph+) acute lymp...